http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#head http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU http://www.nanopub.org/nschema#hasAssertion http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#assertion http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU http://www.nanopub.org/nschema#hasProvenance http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#provenance http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU http://www.nanopub.org/nschema#hasPublicationInfo http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#publicationInfo http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#assertion http://bio2rdf.org/drugbank:DB00872 http://bio2rdf.org/drugbank_vocabulary:ddi-interactor-in http://bio2rdf.org/drugbank_resource:DB00872_DB01394 http://bio2rdf.org/drugbank:DB01394 http://bio2rdf.org/drugbank_vocabulary:ddi-interactor-in http://bio2rdf.org/drugbank_resource:DB00872_DB01394 http://bio2rdf.org/drugbank_resource:DB00872_DB01394 http://purl.org/dc/terms/identifier drugbank_resource:DB00872_DB01394 http://bio2rdf.org/drugbank_resource:DB00872_DB01394 http://purl.org/dc/terms/title DDI between Conivaptan and Colchicine - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. In patients with normal renal and hepatic function, reduce colchicine dose (for gout flares: to 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later, with next dose no sooner than 3 days later; for gout flare prophylaxis: if target dose would otherwise be 0.6 mg daily, change to 0.3 mg every other day, and if target dose would otherwise be 0.6 mg twice daily, change to 0.3 mg daily; for Familial Mediterranean Fever: to no more than 0.6 mg/day) when using in combination with a strong CYP3A4 inhibitor such as clarithromycin or ritonavir. Increase monitoring for colchicine-related toxicity when using such combinations. Colchicine use is contraindicated in patients with impaired renal and/or hepatic function who are also receiving a strong CYP3A4 inhibitor. http://bio2rdf.org/drugbank_resource:DB00872_DB01394 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://bio2rdf.org/drugbank_vocabulary:Drug-Drug-Interaction http://bio2rdf.org/drugbank_resource:DB00872_DB01394 http://www.w3.org/2000/01/rdf-schema#label DDI between Conivaptan and Colchicine - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. In patients with normal renal and hepatic function, reduce colchicine dose (for gout flares: to 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later, with next dose no sooner than 3 days later; for gout flare prophylaxis: if target dose would otherwise be 0.6 mg daily, change to 0.3 mg every other day, and if target dose would otherwise be 0.6 mg twice daily, change to 0.3 mg daily; for Familial Mediterranean Fever: to no more than 0.6 mg/day) when using in combination with a strong CYP3A4 inhibitor such as clarithromycin or ritonavir. Increase monitoring for colchicine-related toxicity when using such combinations. Colchicine use is contraindicated in patients with impaired renal and/or hepatic function who are also receiving a strong CYP3A4 inhibitor. [drugbank_resource:DB00872_DB01394] http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#provenance http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#assertion http://semanticscience.org/resource/SIO_000253 http://bio2rdf.org/drugbank_resource:bio2rdf.dataset.drugbank.R3 http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#publicationInfo http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#signature.MCwCFFai67Gw3auS http://purl.org/nanopub/x/hasPublicKey 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 http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#signature.MCwCFFai67Gw3auS http://purl.org/nanopub/x/hasSignature MCwCFFai67Gw3auSxAb4sf1WOLofLituAhRmsgY2hBQ9U9y4ggOS/HGImRaG7A== http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#signature.MCwCFFai67Gw3auS http://purl.org/nanopub/x/signedBy https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU http://purl.org/dc/terms/created 2018-03-30T11:12:24.104+02:00 http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU http://purl.org/dc/terms/license https://creativecommons.org/licenses/by-nc/4.0/ http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU http://purl.org/nanopub/x/hasSignatureElement http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU#signature.MCwCFFai67Gw3auS http://bio2rdf.org/drugbank_resource:DB00872_DB01394_nanopub.RAiiBAV8yulm7kJ7Ss80HkKczGDnNQXOHUfx0Frn-8QAU http://www.w3.org/ns/prov#wasGeneratedBy https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://www.w3.org/ns/prov#specializationOf https://github.com/tkuhn/bio2rdf2nanopub https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB http://www.w3.org/ns/prov#wasAttributedTo http://orcid.org/0000-0002-1267-0234 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://purl.org/dc/terms/identifier 3c184e6c-ceb8-4275-a679-71dfbdac2a11 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://www.w3.org/ns/prov#used https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://www.w3.org/ns/prov#wasAssociatedWith https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11 http://www.w3.org/ns/prov#wasStartedBy http://orcid.org/0000-0002-1267-0234 https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://purl.org/dc/terms/isVersionOf https://github.com/tkuhn/bio2rdf2nanopub https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://purl.org/pav/version eda7951a5f6c622c5d2132f50c3093138484a349 https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349 http://www.w3.org/ns/prov#wasAttributedTo http://orcid.org/0000-0002-1267-0234